Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease

NARecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

May 31, 2027

Conditions
Autonomic Function
Interventions
OTHER

Oral glucose tolerance test with double-tracer dilution and atropine infusion

Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Atropine infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.

OTHER

Oral glucose tolerance test with double-tracer dilution and saline infusion (placebo)

Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Saline infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.

Trial Locations (1)

89081

RECRUITING

Ulm University Hospital, Ulm

All Listed Sponsors
lead

University of Ulm

OTHER